Karina D. L.
- Country
- The Netherlands
- Department
- 1303: Rheumatology
Research Overview
- Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study
- Long-Term Safety and Tolerability Assessment of Dapirolizumab Pegol in Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Extension Study
- Evaluation of Dapirolizumab Pegol Efficacy and Safety in Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 88 of 167 partner sites.
Specializations
Autoimmune Disease Management
This investigator specializes in treating systemic lupus erythematosus (SLE), with particular emphasis on developing innovative therapeutic approaches for patients with active disease presentations.
- Standard of care optimization
- Novel biological therapies
- Long-term disease management
The research focus includes evaluating emerging treatments alongside established therapeutic protocols for SLE patients.
Lupus Nephritis Research
Specialized investigation in lupus nephritis, focusing on advanced therapeutic interventions for patients with kidney complications related to SLE.
- Refractory disease management
- Cellular therapy applications
- Kidney function preservation
The investigator explores targeted treatments for patients with complex manifestations of lupus-related kidney damage.
Immunotherapy Innovation
Expert focus on immunological interventions including the study of combined therapeutic approaches and novel biological agents for SLE treatment.
- B-cell targeted therapies
- Combination treatment strategies
- Autoimmunity modification
Investigation centers on innovative immunological approaches to achieve better disease control in SLE patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.